Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
79 hedge funds and large institutions have $464M invested in Syros Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 5 closing their positions.
300% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 5
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
75% more capital invested
Capital invested by funds: $266M → $464M (+$199M)
23% more funds holding
Funds holding: 64 → 79 (+15)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$23.5M |
| 2 |
BlackRock
New York
|
+$4.55M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.09M |
| 4 |
Two Sigma Investments
New York
|
+$2.22M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$23.9M |
| 2 |
DM
Deerfield Management
New York
|
-$7.53M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.65M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$1.9M |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$1.8M |
SYRS Hedge Fund Activity: Q2 2020 in Review
79 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2020, worth a combined $464M — up 75% from $266M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SYRS positions and 5 closed out — a net gain of 15 holders — while 36 added to existing stakes and 16 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $23.5M. The largest seller was Arch Venture Management, cutting an estimated $23.9M.
- 79 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2020, up from 64 in Q1 2020.
- Funds reported $464M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 75% quarter-over-quarter.
- 20 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 5 closed out, a net change of +15 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was ARK Investment Management, an estimated $23.5M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Arch Venture Management, an estimated $23.9M sold.
Based on aggregated 13F filings for Q2 2020.